Mechanisms of Salivary Gland Secretory Dysfunction in Sjögren’s Syndrome by Kaleb M. Pauley et al.
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1. Introduction 
Sjögren’s syndrome (SS) is a systemic chronic autoimmune disorder affecting exocrine 
organs such as the salivary and lacrimal glands. SS is characterized by severe dryness of the 
mouth and eyes due to inflammatory reactions against salivary and lacrimal glands, 
respectively. Dryness of other mucosal surfaces such as skin, gastrointestinal tract, lungs, 
and vagina, has also been observed. SS patients also exhibit systemic symptoms such as 
Raynaud’s phenomenon, arthritis, fatigue, peripheral neuropathies, and cognitive 
impairment. SS exists in two forms: primary SS, unassociated with other autoimmune 
disesases; and secondary SS, accompanied by another autoimmune disease such as 
scleroderma, rheumatoid arthritis, or systemic lupus erythematosus (Fox and Kang 1992). SS 
is the second most common autoimmune rheumatic disease, with a prevalence in the United 
States estimated at 2-4 million people (Kassan and Moutsopoulos 2004), with a female to 
male ratio of 9:1. Although SS affects men and children as well, it is most commonly seen if 
peri- or postmenopausal women. 
Diagnostic criteria for SS have been defined most recently by the modified American-
European Consensus Group (Vitali et al. 2002). These criteria include histological evaluation 
of a minor salivary gland for lymphocytic infiltration, serological presence of autoantibodies 
against SSA or SSB antigens, and assessment of ocular and oral symptoms. Oral 
involvement is assessed by the patient’s subjective symptoms of oral dryness, parotid 
sialography showing the presence of diffuse sialectasis, salivary scintigraphy showing 
delayed uptake, reduced concentration, and/or delayed excretion of tracer, and/or the 
evaluation of unstimulated saliva production. Ocular involvement is assessed by the 
patient’s subjective symptoms of ocular dryness, a Schirmer’s test to measure tear secretion 
or a Rose Bengal test to measure the ocular surface abrasion in patients. 
Originally, it was thought that loss of secretory function, a clinical hallmark of SS, was due 
to apoptotic destruction of acinar cells mediated by CD8+ T lymphocytes in the lymphocytic 
infiltration in the salivary and lacrimal glands. However, research has demonstrated that 
transfer of human SS patient IgG to the B-cell deficient SS-prone NOD mouse resulted in 
altered saliva production in the absence of immune cell infiltration in the glands, indicating 
a role for autoantibodies in the functional impairment of secretory processes in SS 
(Robinson, Brayer et al. 1998). This resulted in a paradigm shift in the field, leading to the 
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belief that lymphocytic infiltration was not the only contributing factor to secretory 
dysfunction in SS. In addition to autoantibodies targeting muscarinic receptors, pro-
inflammatory cytokines have been shown to play a role in SS pathogenesis by contributing 
to damage of glandular tissue and secretory dysfunction. Nitric oxide production has also 
been implicated as a potential cause of loss of secretion, as loss of nitric oxide synthase 
activity in salivary glands paralleled the decline in salivary secretion. A role for apoptotic 
cell death of acinar cells still remains in SS pathogenesis, however; our group has 
demonstrated that increased apoptosis is detectable in the salivary glands of SS-prone mice 
prior to disease onset or lymphocytic infiltration (Bulosan et al. 2008). In this review, these 
mechanisms and other possibilities that can contribute to loss of secretory function in SS will 
be discussed in detail.  
2. Mechanisms 
The clinical hallmark of SS is dryness due to loss of secretory function in the salivary and 
lacrimal glands. However, the etiology of SS is still not understood. There are numerous 
underlying mechanisms thought to contribute to this loss of secretory function in salivary 
glands, though no single mechanism has been identified as the primary cause. Lymphocytic 
infiltration, autoantibodies targeting muscarinic receptors, pro-inflammatory cytokines, 
nitric oxide, and apoptotic cell death of acinar cells have all been implicated as potential 
causes of secretory dysfunction in the salivary glands.  
2.1 Lymphocytic infiltration and proinflammatory cytokines in the salivary glands 
SS is characterized by lymphocytic infiltration and aberrant activation of epithelial tissues, 
which appear in salivary and lacrimal glands. It has been reported that this lymphocytic 
infiltration within the salivary and lacrimal glands consists mostly of CD4+ T cells, B cells, 
and lesser numbers of CD8+ T cells (Robinson, Cornelius et al. 1998, ; Tapinos et al. 1998). 
Balance between T and B cells in the lymphocyte infiltrates varies according to disease 
progression in the mouse model of SS (Robinson, Cornelius et al. 1998, ; Tapinos et al. 1998). 
It has been shown that leukocytes expressing pro-inflammatory cytokines infiltrate the 
exocrine glands, and T cells are recruited first to the site of infiltration followed by B cells, 
establishing lymphocytic infiltrates (Kong et al. 1998). CD8+ T cells, which have been shown 
to have increased expression of adhesion molecules and Fas/FasL, can also directly kill 
acinar cells in the salivary glands. Salivary gland dryness and/or formation of lymphocytic 
infiltration may be the result of glandular destruction mediated by effector 
cytokines/chemokines from T and B cells, as well as cytotoxic effects of CD8+ T cells. 
2.1.1 Cytokines contributing to salivary gland dysfunction 
Tumor necrosis factor- ┙ (TNF-┙) is one of the proinflammatory cytokines produced in 
response to infection, tissue damage, and environmental challenges and also known as an 
Interferon-┛ (IFN┛)-inducing cytokine along with IL-12 and IL-18 (Locksley 1993, ; Billiau 
1996). TNF-┙ production has been implicated in many human diseases including 
autoimmune diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE). TNF-┙ activated the extrinsic apoptotic pathway and 
induced upregulation of intercellular adhesion molecule-1 (ICAM-1) and CCL20 in human 
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salivary gland (HSG) cells in vitro (Wang et al. 2009). In addition, TNF-┙ can disrupt tight 
junction structure in salivary glands from SS patients, potentially resulting in secretory 
dysfunction (Ewert et al. 2010, ; Baker 2010). 
IL-18 and its inducer IL-12 are cytokines that play an important role in TH1 driven 
autoimmune responses and inflammatory tissue disease by activating IFN┛ secretion. The 
elevation of these cytokines triggered the inflammatory response in SLE and RA patients 
(Mosaad et al. 2003). Increased circulating levels and salivary gland expression of IL-18 was 
observed in SS patients, and IL-18 was detected in periductal inflammatory foci and saliva 
as well (Bombardieri et al. 2004, ; Bulosan et al. 2009). In addition, increased labial salivary 
gland IL-18 levels in primary SS patients correlated with increased disease activity 
parameters (Bikker et al. 2010, ; Bombardieri et al. 2004). Moreover, salivary gland 
infiltration by macrophages and dendritic cells (DCs), along with the expression of IL-18 
and IL-12, appear to play active roles in the expansion and organization of infiltrative 
injuries and have a correlation with the lymphoma development in the patients with 
primary SS (Manoussakis et al. 2007). IL-12 transgenic mice showed decreased stimulated 
salivary flow by pilocarpine than in wild type controls. Also, IL-12 transgenic mice exhibited 
increased number and size of lymphocytic foci with increased anti-SSB/La antibodies, 
compared to glands from age-matched controls (Vosters et al. 2009). 
IFN┛ is the major cytokine which is released from TH1 cells and regulates cell-mediated 
immune responses through activation of natural killer (NK) cells, macrophages, and CD8+ T 
cells. IFN-┛ or receptor knockout mouse models (NOD. IFN┛-/- and NOD. IFN┛R-/-) showed 
normal development of salivary glands, maintained secretory function, and failed to 
develop any SS-like phenotypes (Cha et al. 2004). However, its parental strain NOD and a 
recently developed SS mouse model C57BL/6.NOD-Aec1Aec2 showed retarded salivary 
gland growth and acinar cell apoptosis prior to disease onset and proceed to developing 
full-blown disease phenotype including loss of secretory function (Lee, Tudares, and 
Nguyen 2009). This indicates that IFN-┛ plays an important role in loss of secretory function 
in SS. In addition, it has been found that IFN┛-induced T cells can produce chemokines 
(IFN-inducible protein 10 (IP-10)/CXCL9, CXCL10), which can attract NK cell and T cells in 
SS ductal epithelial cells (Ogawa et al. 2002, ; Ogawa et al. 2004). 
There are also cytokines released from TH2 cells that can play an important role in SS. 
Elevated levels of IL-4 were found in the serum of primary SS patients who have 
lymphocytic infiltration and ectopic germinal center formation in their minor salivary 
glands (Reksten et al. 2009). Studies using the NOD.IL4–/– and NOD.B10-H2b.IL4–/– mice 
indicated that IL-4 gene knockout mice have pathophysiological abnormalities and 
leukocyte infiltration in the salivary glands but salivary gland secretion was normal in the 
absence of IL-4 (Gao et al. 2006). Considering that IL-4 knockout mice fail to produce IgG1 
isotypic autoantibodies against cell surface receptor muscarinic type 3 receptor (M3R), 
isotypic anti-M3R autoantibody is critical in the development of secretory dysfunction (Gao 
et al. 2004). Moreover, purified IgG fractions isolated from the sera of Stat6 (downstream 
signal transduction factor of IL-4) knockout mice, which are unable to produce IgG1, were 
not able to inhibit saliva flow rates when infused to wild type control mice (C57BL/6) 
(Nguyen et al. 2007). Therefore, IL-4 can affect saliva secretion via antibody production and 
its isotype switching. 
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Recently, not only TH1 and TH2 effector cells but also TH17 cells, which mainly release pro-
inflammatory cytokine IL-17, are being investigated for their role in disease pathogenesis of 
many autoimmune diseases including SS. The presence of TH17 cells and TH17-associated 
cytokines, IL-6, IL-23, IL-17, and IL-1┚ were reported in the serum and minor salivary 
glands of primary SS patients (Nguyen et al. 2008, ; Sakai et al. 2008, ; Reksten et al. 2009, ; 
Katsifis et al. 2009). It is also known that IL-18 synergizes with IL-17 to induce secretion of 
pro-inflammatory cytokines IL-6 and IL-8 in human parotid gland cells (Sakai et al. 2008). 
Serum levels of IL-17, IL-6, and IL-23 were significantly elevated in primary SS. A recent 
study in which an adenovirus vector expressing IL-17 was infused into the salivary glands 
of wild type mice (C57BL/6J) demonstrated the appearance of lymphocytic infiltrates, 
increased proinflammatory cytokine levels, changes in antinuclear antibody profiles, and 
temporal loss of saliva flow after infusion (Nguyen et al. 2010). In the reverse approach, 
infusion of IL-17R:Fc-blocking factor into the SS mouse model to block IL-17 binding to IL-
17 receptor showed decreased lymphocytic infiltration in salivary glands, normalization of 
the antinuclear antibody repertoire, and increased saliva secretion (Nguyen et al. 2011). 
Therefore, these studies indicate that IL-17 is critical in inducing SS-phenotype in wild type 
mice. However, the mechanism by which IL-17 functions in altering secretory function in SS 
needs to be defined. 
2.1.2 B cell involvement in SS 
In addition to pathogenic T cells and cytokines, loss of B cell tolerance is critical in 
autoimmune diseases including SS. Levels of the B cell activating factor belonging to the 
TNF family (BAFF) in serum were higher in patients with SLE, RA and pSS than in normal 
individuals (Cheema et al. 2001, ; Groom et al. 2002, ; Zhang et al. 2001). BAFF 
overexpression caused self-reactive B cells at the transitional B cell stage and is responsible 
for B cell hyperactivity. It is known that over-expressing BAFF in BAFF-transgenic mice 
resulted in SLE-like disease with increased number of marginal-zone (MZ) like B cells, and 
at 16-18 months of age, these mice exhibited a SS-like disease with MZ like B cells in the 
salivary glands (Mackay et al. 1999, ; Groom et al. 2002). However, recent findings indicated 
that BAFF expression alone is not correlated with disease activity (Cheema et al. 2001, ; 
Zhang et al. 2001, ; Stohl et al. 2003). Nonetheless, BAFF influences the survival, 
proliferation, and differentiation of B cells in combination with IL-17 in patients with SLE 
and its combination can promote the persistence of self-reactive B cells (Doreau et al. 2009). 
As described above, T cells and B cells clearly contribute to SS onset and progression. 
However, activation of T cells and B cells are required for normal immune function, and the 
trigger for autoimmune reactivity in SS has yet to be identified. Also, studies using immune-
deficient mice revealed that secretory dysfunction and other salivary gland abnormalities 
can still occur in the absence of infiltrating immune cells and their cytokines. 
2.2 Autoantibodies targeting muscarinic receptors 
The assumption that secretory dysfunction in SS was a direct consequence of acinar tissue 
loss after lymphocytic infiltration was deeply ingrained in the SS research community for 
more than 60 years. However, more recently, our understanding of the pathogenesis of 
secretory dysfunction in SS has undergone a dramatic change. Questions arose concerning 
www.intechopen.com
 
Mechanisms of Salivary Gland Secretory Dysfunction in Sjögren’s Syndrome 
 
175 
SS patients with viable acinar tissue in their salivary glands but who still suffer from 
xerostomia. These observations suggest that the salivary gland secretory dysfunction in 
many SS patients is the result of a disruption of acinar cell function rather than acinar tissue 
destruction. 
 
Fig. 1. Immune cell infiltration in the salivary gland of 34 week old SS-prone  
C57BL/6.NOD-Aec1Aec2 male mouse.  
In addition to salivary gland lymphocytic infiltration, SS patients exhibit 
hypergammaglobulinemia with a range of autoanitbodies targeting cell surface, 
cytoplasmic, and nuclear proteins of exocrine tissue (Chan et al. 1991, ; Fox and Kang 1992, ; 
Haneji et al. 1997). Approximately 90% of patients are positive for antinuclear antibodies 
(ANA), the most common of which are directed against two ribonucleoprotein antigens 
known as Ro or SSA and La or SSB. These autoantibodies are included in the modified 
European–American Diagnostic Criteria for Sjögren’s Syndrome (Vitali et al. 2002), but are 
also found in other autoimmune diseases, particularly systemic lupus erythematosus (SLE). 
Autoantibodies to other immunoglobulins (known as rheumatoid factors) are also 
frequently found in SS. Primary SS (pSS) sera can also contain many different 
autoantibodies against organ or tissue specific autoantigens, including acetylcholine 
receptors, the carbonic anhydrase and thyroid peroxidase. Finally, autoantibodies directed 
against the cytoskeletal protein ┚-fodrin, and the muscarinic receptors M3, have also been 
described in primary SS, the latter of which we will focus on here. 
2.2.1 Muscarinic receptor function in salivary glands 
Acetylcholine (ACh) control of fluid secretion in salivary acinar cells is mediated through 
the G protien-linked muscarinic M3 receptor (M3R). ACh binds to M3R, which causes 
phospholipase C to generate inositol 1,4,5-trisphosphate (IP3). IP3 binds to and opens the 
IP3 receptor on the endoplasmic reticulum, which releases Ca2+. The increased concentration 
of intracellular Ca2+ activates the apical membrane Cl- channel and the basolateral  
K+ channel. Efflux of Cl- into the acinar lumen draws Na+ across the cells, and the osmotic 
gradient generates fluid secretion (Tobin, Giglio, and Lundgren 2009). Therefore, blocking 
or desensitizing muscarinic receptors is detrimental to this signaling pathway and 
ultimately results in loss of secretory function. 
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2.2.2 Initial characterization of anti-muscarinic antibodies 
In 1994, it was observed that in the NOD mouse model, which exhibits an autoimmune-
associated lymphocytic attack on the salivary glands and loss of secretory function, 
decreased response to beta-adrenergic receptor stimulation was related to a decrease in 
receptor density and changes in the level of intracellular second messenger signalling (Hu et 
al. 1994). It was hypothesized that these changes could be due to an autoantibody targeting 
the ┚1-adrenergic receptor present in the sera of NOD mice. 
In 1996, futher study of the NOD mouse model revealed a reduction in muscarinic receptor 
density on the salivary glands of prediabetic and diabetic NOD mice compared to BALB/c 
mice corresponding to reduced secretory function in the NOD (Yamamoto et al. 1996). 
Additionally, sera from the diabetic NOD but not the BALB/c immunoprecipitated 
radiolabeled muscarinic receptor, indicating the presence of autoantibody to the receptor in 
NOD mice (Yamamoto et al. 1996). 
Autoantibodies against M3R were first described in human SS patients in 1996 (Bacman et 
al. 1996). It was demonstrated that IgG present in the sera of primary SS patients could bind 
and activate muscarinic receptors of rat parotid glands (Bacman et al. 1996). They also 
demonstrated that the IgG fraction from the sera of pSS patients mimicked the biological 
effects of muscarinic cholingergic agonists by modifying intracellular events associated with 
specific receptor activation, such as decreasing cAMP and increasing phosphoinositide 
turnover (Bacman et al. 1996). These findings suggested that autoantibodies targeting M3R 
could potentially play a role in SS pathogenesis. 
 
Fig. 2. pSS IgG staining of hM3R-transfected Flp-In CHO cells. Flp-In CHO cells were 
transfected with hM3R and then incubated with pSS sera (1:50 dilution) containing  
anti-M3R autoantibodies. Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
antibody at 1:250 dilution was used for detection. 
2.2.3 Roles for anti-muscarinic receptor antibodies in SS 
In 1998, Robinson, et al. were the first to demonstrate that transferring human SS patient IgG 
to NOD.Igµnull mice resulted in secretory gland dysfunction (Robinson, Brayer et al. 1998). 
NOD.Igµnull mice lack functional B lymphocytes, and therefore lack the IgG autoantibodies 
that are produced by their NOD counterparts and human SS patients. NOD.Igµnull mice do 
exhibit lymphocytic infiltration of the salivary and lacrimal glands, but fail to lose secretory 
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function. However, when treated with IgG from SS patient sera, a 54% reduction in saliva 
production was observed, while treatment with IgG from healthy control mice and healthy 
humans had no significant effect on secretory function (Robinson, Brayer et al. 1998). 
Furthermore, after prolonged treatment with SS IgG fractions, there was an increase in 
apoptotic cell death of salivary acinar cells (Robinson, Brayer et al. 1998). These data indicate 
that anti-M3R autoantibodies play a critical role in the clinical presentation of dryness in SS. 
Further evidence for anti-M3R autoantibody-mediated secretory dysfunction in NOD mice 
was presented in 2000. Infusion of monoclonal antibodies to mouse M3R into NOD-scid 
mice resulted in significantly reduced saliva secretion within 72 hours, while infusion with 
antibodies to Ro (SSA), La (SSB), or parotid secretory protein (PSP) had no effect on 
secretory function (Nguyen et al. 2000). Mechanistic studies revealed that translocation of 
aquaporin-5 to the plasma membrane was inhibited by anti-M3R antibodies, but not the 
other antibodies again showing a role for anti-M3R autoantibodies in SS pathogenesis 
(Nguyen et al. 2000).  
In 2004, Li, et al. demonstrated the inhibitory effects of autoantibodies from SS patients on 
muscarinic receptors by showing that carbachol-induced intracellular calcium release was 
inhibited by SS IgG treatment of HSG cells (Li et al. 2004). Aquaporin-5 trafficking to the 
apical membrane of rat parotid acinar cells was also inhibited by SS IgG (Li et al. 2004). 
Additionally, other groups found abnormal translocation of aquaporin-5 in the NOD mouse 
model of SS and in salivary glands of SS patients (Konttinen et al. 2005, ; Steinfeld et al. 
2001). However, these findings are somewhat controversial since others have shown no 
differences in the subcellular distribution of aquaporin-5 in salivary glands of primary SS 
patients (Beroukas et al. 2001, ; Tsubota et al. 2001). Our unpublished findings show a 
definite alteration in GFP-tagged aquaporin-5 trafficking in human salivary gland cells that 
were pre-treated with SS plasma compared to healthy control plasma. Taken together, these 
data further support a role for anti-muscarinic receptor autoantibodies in loss of secretory 
function in SS. 
The chronic effects of anti-M3R autoantibodies were examined in 2006 by analyzing the 
contraction of bladder smooth muscle strips from diseased NOD mice (Cha et al. 2006). The 
results indicated that the presence of anti-M3R autoantibodies in NOD mice resulted in a 
desensitization of M3R as measured by direct carbachol-induced responses and an 
accelerated loss of responses to repeated pilocarpine injections (Cha et al. 2006). This data 
supports the hypothesis that frequent use of pilocarpine by SS patients who have already 
progressed to M3R desensitization induced by anti-M3R autoantibodies will be less effective 
due to a desensitizing synergy between pilocarpine and anti-M3R autoantibodies. 
Anti-muscarinic receptor antibodies have also been shown to affect the autonomic nervous 
system. In 2000, it was demonstrated that sera from primary and secondary SS patients 
inhibited parasympathetic neurotransmission as measured by carbachol-stimulated bladder 
contraction using bladder and colon smooth muscle strips in vitro, while sera from healthy 
controls or SLE patients had no effect (Waterman, Gordon, and Rischmueller 2000). These 
findings suggest that autoantibodies targeting M3R may contribute to sicca symptoms as 
well as autonomic dysfunction such as bladder symptoms in some patients (Waterman, 
Gordon, and Rischmueller 2000).  
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In vivo evidence was presented in 2004, when passive transfer of SS IgG with anti-M3R 
activity to BALB/c mice resulted in an increased response to cholinergic stimulation of 
bladder smooth muscle (Wang et al. 2004). This cholinergic hyperresponsiveness was found 
to be specifically induced by anti-M3R antibodies following passive transfer (Wang et al. 
2004). These findings are consistent with the overactive bladder symptoms experienced by 
many SS patients, indicating that overactive bladder in SS is an autoantibody-mediated 
disorder of the autonomic nervous system that could also account for a broad range of 
cholinergic hyperresponsiveness. 
Most recently, it has been demonstrated that primary SS IgG with anti-M3R activity 
inhibited contraction of the smooth muscle of the GI tract and disrupted contractile motility 
in the colon (Park et al. 2011). These data may explain the widespread impairment of the GI 
tract in SS patients including delayed gastric emptying and abnormalities in colonic motility 
(Cai et al. 2008, ; Kovacs et al. 2003).  
2.2.4 Conclusions 
Overall, these findings strongly support a role for anti-M3R autoantibodies in the 
pathogenesis of SS. The data suggest that a number of primary and secondary SS patients 
have serum IgG capable of binding to and inhibiting muscarinic receptors on salivary acinar 
cells in vitro. However, due to the lack of a reliable screening assay, relatively few subjects 
have been tested, and the percentage of SS patients estimated to be positive for anti-
muscarinic antibodies varies wildly from 0 to almost 100%. Future studies in this field 
should focus on the development of a screening assay for anti-muscarinic antibodies to 
confirm the number of SS patients positive for these autoantibodies and establish or rule-out 
anti-M3R antibodies as a diagnostic marker for SS.  
2.3 Nitric oxide and nitric oxide synthase 
In 1986 nitric oxide (NO) was first described as endothelially derived relaxing factor (EDRF) 
(Palmer, Ferrige, and Moncada 1987). Subsequently, it has been shown to be involved in a 
multitude of diverse physiological and pathophsiological processes, including potential 
functions in the regulation of salivary gland secretion and in the development of secretory 
hypofunction. In vivo, NO is found to be synthesized in a wide variety of cell types by the 
enzyme NO synthase (NOS). There are three known isoforms of NOS, each produced from a 
distinct set of genes. The two constitutive isoforms are neuronal NOS (nNOS, NOS-1) and 
endothelial NOS (eNOS, NOS-3), whereby their names reflect the original tissues from 
which they were discovered. The functional activity of these two isoforms is dependent on a 
rise in Ca2+ and therefore generate low, transient, concentrations of NO. The other isoform, 
inducible NOS (iNOS, NOS-2), is mainly found in inflammatory cell types including: 
macrophages, neutrophils, and fibroblasts (Knowles and Moncada 1994). Expression of 
iNOS can be induced by bacterial lipopolysaccharides (LPS) and inflammatory cytokines. 
The concentrations of NO produced by iNOS are much greater than either eNOS or nNOS, 
and at levels that are typically cytotoxic and bactericidal (Kimura-Shimmyo et al. 2002).  
2.3.1 Sources of NO in human salivary glands 
The increased presence of nitrite (NO2-, the oxygenation product of NO) in the saliva of 
healthy individuals in response to stimulated secretion (Bodis and Haregewoin 1993) 
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implies a system by which endogenous, constitutively expressed, NO may be produced in 
glandular cells and in turn alter saliva secretion. Surprisingly, immunohistochemical 
analyses of human minor and major salivary glands revealed that nNOS is strongly 
restricted to the non-neuronal duct epithelium and only a minority of the major salivary 
gland nerve fibers (surrounding acini, tubuli, ducts and blood vessels) expressed nNOS 
(Soinila, Nuorva, and Soinila 2006). In addition, salivary gland acinar cells have been 
demonstrated to express NOS (Looms et al. 2002, ; Looms et al. 2000, ; Soinila, Nuorva, and 
Soinila 2006). Human labial salivary gland acinar cells possess NOS activity and exhibit a 
very low level of NO production without stimulation in vitro (Looms et al. 2000). 
Stimulation of NO production, with a concomitant rise in Ca2+, in human labial acinar cells 
was shown to be directly mediated through activation of ┚-adreneric receptors, which could 
not be mimicked by a rise in Ca2+ alone (Looms et al. 2000). As expected, the expression of 
eNOS in human minor and major salivary glands is restricted mostly to the vascular 
endothelium (Soinila, Nuorva, and Soinila 2006). The constitutive expression of NOS and 
NO in human salivary gland acini and ducts suggests a potential contribution to secretion. 
However, their exact roles in healthy salivary glands are still undetermined.  
2.3.2 Potential function of NO in secretion 
Saliva secretion signaling pathways and mechanisms have been studied closely, where the 
involvement of NO in these pathways is still of great interest. The classical signaling 
pathway involves autonomic receptor stimulation of acinar cells, which leads to increased 
IP3-mediated intracellular Ca2+ release from the endoplasmic reticulum and cAMP 
activation of protein phosphorylation. An additional receptor/channel involved in the 
release of Ca2+ from intracellular stores is the ryanodine receptor (RyR), of which, cyclic 
ADP-ribose (cADPR) has been suggested as an endogenous ligand (Galione, Lee, and Busa 
1991, ; Looms et al. 2001). One potential means by which endogenous NO exerts an effect in 
the salivary gland acinar cells is by binding to the heme moiety of soluble guanylyl cyclases 
(Denninger and Marletta 1999) thus activating the synthesis of cyclic guanosine 
monophosphate (cGMP), which can promote the synthesis of the Ca2+-mobilizing cADPR 
(Galione et al. 1993, ; Looms et al. 2001, ; Willmott et al. 1996). This NO-induced intracellular 
Ca2+ release is proposed to coordinate cellular activation and to have a role in determining 
the magnitude and time course of the secretory response (Caulfield et al. 2009, ; Harmer, 
Gallacher, and Smith 2001). Alterations in this response could play a role in salivary gland 
hypofunction via a disruption in the normal Ca2+ signaling pathways.  
2.3.3 Potential roles of NO and iNOS in exocrine hypofunction 
Evidence suggests that the loss of secretory function associated with SS may occur due to 
factors which alter Ca2+ signaling and not only through direct tissue destruction by 
infiltrating lymphocytes. One hypothesis for salivary gland exocrine hypofunction is based 
from the observation that the sera from NOD mice, prone to developing SS, were found to 
contain autoantibodies against ┚-adrenergic and muscarinic receptors (Hu et al. 1994, ; 
Yamamoto et al. 1996). The blockage of the ┚-adrenergic agonist binding down-regulated 
receptor density due to the chronic stimulation (Hu et al. 1994). Therefore, according to the 
previously described model for NO-induced Ca2+ release, saliva secretion could be 
diminished due to blockage of these receptors (Looms et al. 2002).  
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On the contrary, elevated nitrite is present at increased concentrations in SS patient saliva 
and serum compared to healthy controls (Konttinen et al. 1997, ; Wanchu et al. 2000). The 
effects of this possible elevation in NO concentration has been explored in recent 
experiments where the acute exposure of NO to human submandibular gland acinar cells 
were able to transiently (20-30 minutes) enhance Ca2+ signaling, but a more chronic 
exposure to NO eventually desensitized these cells to stimulation (Caulfield et al. 2009). The 
mechanism by which NO exerts its inhibitory effects on the stimulation of secretion is still 
not understood, but it is most likely not mediated through cGMP nor due to a depletion of 
the Ca2+ stores. It is hypothesized that the inhibition of activity could be due to the NO-
mediated nitrosylation of receptors or other proteins involved in the secretion signal 
transduction pathways (Caulfield et al. 2009). However, this relationship between increased 
nitrite concentrations and salivary gland hypofunction is more complicated, since other oral 
inflammatory disorders exhibit increased nitrite concentrations in saliva as well (Kendall et 
al. 2000, ; Kendall, Marshall, and Bartold 2001, ; Ohashi, Iwase, and Nagumo 1999).  
The role of iNOS in the loss of secretory function has also been investigated due to the pro-
inflammatory environment present in the salivary glands of SjS patients. As expected, iNOS 
expression is increased in resident cells of the labial salivary glands of patients with SS when 
compared to healthy controls (Konttinen et al. 1997). Cytokines (for example: IFN-┛, IL-18, 
IL-1┚ and TNF-┙) or LPS induction of iNOS leads to a significant increase in NO production 
(Dinarello 1997, ; Kimura-Shimmyo et al. 2002, ; Liew 1994). NO production from iNOS is 
long-lasting and at relatively high concentrations when compared to the other two Ca2+-
dependent isotypes (Nathan and Xie 1994). This increased NO has been hypothesized to 
directly nitrosylate functional proteins and thus could induce cell death by potentially 
disrupting essential cellular processes (Kimura-Shimmyo et al. 2002, ; Sarih, Souvannavong, 
and Adam 1993). In another course of altering cellular functioning, the product of the 
reaction of NO with superoxide, peroxynitrite, has also been suggested to promote 
modulations of cell signaling and even produce oxidative injury (Pacher, Beckman, and 
Liaudet 2007). It has been shown in several cases how the upregulation of iNOS expression 
may ultimately lead to secretory hypofunction due to the accumulated damage from NO 
(Dawson, Fox, and Smith 2006, ; Kimura-Shimmyo et al. 2002, ; Konttinen et al. 1997, ; 
Takeda et al. 2003).  
2.4 Altered glandular homeostasis 
In addition to the immune cell-mediated mechanisms that contribute to secretory gland 
dysfunction, there is also evidence for altered glandular homeostasis in SS glands that 
appears even prior to disease onset. Specifically, aberrant expression and proteolytic 
cleavage of PSP, increased serine and cysteine protease enzyme activity, elevated numbers 
of apoptotic cells, enhanced matrix metalloproteinase activities in salivary gland lysates and 
decreased amylase activity and epidermal growth factor gene expression are all observed 
irrespective of the presence of lymphocytic infiltration or detectable autoimmune 
phenotype. Additionally, submandibular glands of NOD neonates revealed some 
genetically programmed glandular defects such as retarded salivary gland development. 
How these early defects influence the onset and development of SS is still under active 
investigation. 
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2.4.1 Defects in salivary glands of NOD mouse models after disease onset 
NOD mice develop chronic lymphocytic infiltration in the salivary glands that correlate 
with decreased saliva production concurrently with infiltration in the pancreas that results 
in phenotypes similar to insulin-dependent diabetes mellitus and SS. To differentiate 
between immune cell-mediated and non-immune cell-mediated mechanisms in the SS 
phenotype, salivary glands were characterized in NOD-scid mice and other NOD 
derivatives. 
In the absence of a functional immune system, the salivary flow rate of >20 week old NOD-
scid is similar to 10-12 week old mice (Robinson et al. 1996). However, saliva analysis 
revealed that epidermal growth factor (EGF, a product of submandibular gland ductal cells) 
and amylase (a product of salivary acinar cells) were significantly decreased in the saliva of 
>20 week old NOD-scid compared to 10-12 week old mice (Robinson et al. 1996). 
Additionally, PSP was detected in submandibular gland lysates of 10 week old NOD-scid 
and increased in quantity by 20 weeks of age, while PSP was not detected in control BALB/c 
glands, and (Robinson et al. 1996). Histological examination of NOD-scid submandibular 
glands revealed a progressive loss of acinar tissue and a decline in the acinar to ductal cell 
ratio in the absence of lymphocytic infiltrates (Robinson et al. 1996). These differences in 
salivary protein composition and glandular histology in the absence of lymphocytic 
infiltration indicate that glandular defects in the NOD genetic background may contribute to 
the onset of the autoimmune reaction in the salivary glands. 
Further analysis of these findings revealed increased cysteine protease activity in the saliva 
and gland lysates of 20 week old NOD and NOD-scid mice compared to age matched 
BALB/c or 8 week old NOD mice (Robinson et al. 1997). This increased activity was highest 
in the NOD-scid mice indicating that infiltrating immune cells are not responsible for these 
changes. Additional protease activity in the saliva and gland lysates of older NOD and 
NOD-scid mice generated an enzymatically cleaved PSP (Robinson et al. 1997). These 
findings suggest that proteolytic enzyme activity contributes to loss of exocrine gland 
tolerance by generating abnormally processed protein constituents. 
2.4.2 Defects in salivary glands of NOD mice prior to disease onset 
The changes in the protein composition of saliva, PSP expression, and protease activity in 
the absence of lymphocytic infiltration or functional immune cells indicate that innate 
genetic differences in the NOD salivary glands exist and may contribute to the SS 
phenotype. To further support this theory, salivary gland organogenesis was examined in 
neonatal NOD mice and compared to wild type mice (Cha et al. 2001). Histomorphological 
analyses of submandibular glands at 1 day postpartum revealed delayed morphological 
differentiation during organogenesis in NOD mice compared to wild type mice, acinar cell 
proliferation was reduced, and expression of Fas, FasL and bcl-2 were increased (Cha et al. 
2001). Prior to weaning (up to 21 days) the NOD strains showed increased matrix 
metalloprotease (MMP)-2 and MMP-9 activity (Cha et al. 2001). This altered glandular 
development may contribute to an environment capable of triggering autoimmunity. 
As mentioned previously, a role for interferon-┛ (IFN-┛) in these pre-disease aberrations was 
discovered when neither NOD.IFN┛ -/- and NOD.IFN┛R-/- mice exhibited increased acinar 
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cell apoptosis or abnormal salivary protein expression prior to disease (Cha et al. 2004). 
Strikingly, without these abnormalities, the NOD.IFN┛ -/- and NOD.IFN┛R-/- mice showed 
no autoimmune attack of the salivary glands at 20 weeks old (Cha et al. 2004). Also, NOD-
scid.IFNγ -/- mice, unlike NOD-scid and NOD, showed normal glandular morphogenesis at 
birth (Cha et al. 2004). These data suggest that IFN-┛ has a critical role during the pre-
immune phase disease independent of effector functions of immune cells. 
 
Fig. 3. Increased epithelial cell death in the glands of disease-prone mice at 8 weeks and lack 
of direct colocalization of caspase-11 with TUNEL-positive cells. (A) TUNEL staining was 
performed on the prediseased salivary glands; upper panel at × 10 and lower panel at × 40 
magnifications. (B) Percentages of TUNEL-positive cells are shown as a bar graph. For each 
mouse, three slides were evaluated for TUNEL-positive cells, which were counted using a 
cell counter. (C) Caspase-3-positive cells (yellow arrows in b) were colocalized with 
TUNEL-positive cells (red arrows). White arrows indicate caspase-11-positive cell. 
Magnification, × 40. NC, negative control; PC, positive control treated with nuclease; 
TUNEL, transferase-mediated dUTP-biotin nick end labeling. Figure previously published 
in (Bulosan et al. 2009). 
The NOD mouse model was/is used extensively to study SS pathogenesis; however, this 
model is genetically predisposed to develop at least three autoimmune diseases. To create a 
primary SS mouse model that only exhibits SS-like phenotype, two chromosomal intervals 
from the NOD mouse that conferred sialadenitis were bred to non-autoimmune C57BL/6 
mice (Cha et al. 2002). These mice, designated C57BL/6.NOD-Aec1Aec2, enabled the study 
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of disease-associated genes alone, and were used to characterize early pathogenic events 
associated with SS-like disease through microarray analysis of gene expression in the 
salivary glands during the pre-disease stage (Killedar et al. 2006). Interestingly, 
C57BL/6.NOD-Aec1Aec2 exhibited upregulated genes encoding proteins associated with 
IFN-┛ signal transduction pathway (Jak/Stat), TLR-3 (Irf3 and Traf6), and apoptosis (casp11 
and casp3) compared to C57BL/6 (Killedar et al. 2006).  
The upregulation of caspase-11 in 8 week old C57BL/6.NOD-Aec1Aec2 mice was detected in 
our study. Concomitantly, apoptotic cells were more readily detected in this mouse model 
compared to wild type mice. Further studies were then conducted to determine whether 
upregulated caspase-11 is responsible for this phenomenon. In these studies it was shown 
that the upregulated caspase-11 expression from the salivary glands activated caspase-1, but 
not caspase-3. In effect, apoptotic cells were not positive for caspase-11 staining, suggesting 
that caspase-11 plays an indirect role in increased apoptotic acinar cell death in the salivary 
glands before disease onset (Bulosan et al. 2009). This finding led to the hypothesis that 
inflammatory caspases, such as caspase-11 indirectly functions in apoptosis by activating 
caspase-1 and resulting in the subsequent release of proinflammatory cytokines into the 
glandular environment. This hypothesis was tested by co-culturing human salivary gland 
cells with a human monocyte cell line, THP-1, stimulated with LPS in the presence or 
absence of IFN-┛. In the presence of IFN-┛, there was an increased rate of HSG cell 
apoptosis, but when caspase-1 was knocked down by small interfering RNA in the THP-1 
cells, the rate of apoptosis in HSG cells was reversed back to normal (Bulosan et al. 2009). 
These data indicate that the increased caspase-11 expression in macrophages and dendritic 
cells present in the salivary glands of 8 week old C57BL/6.NOD-Aec1Aec2 mice may 
increase apoptotic cell death of surrounding acinar cells by activating capase-1, resulting in 
the secretion of pro-inflammatory cytokines IL-1┚ and IL-18. In other words, inflammatory 
caspases are essential in promoting a pro-inflammatory microenvironment and influencing 
salivary gland cell death prior to disease onset. 
2.4.3 Altered microRNA expression in SS 
MicroRNAs (miRNAs) are small non-coding RNA molecules that post-transcriptionally 
regulate gene expression by binding to the 3’ untranslated regions of specifc mRNAs and 
blocking translation or causing degradation. Recently, miRNAs have been implicated in a 
number of diseases including autoimmune disorders. In 2011, it is becoming clear that 
miRNAs may also play a role in SS, although that specific role has yet to be determined. 
Alevizos, et al. demonstrated that miRNA expression patterns can accurately distinguish 
salivary glands from control subjects and SS patients, and that comparing miRNA from 
patients with preserved or low saliva flow identified a set of differentially expressed 
miRNAs, indicating a potential role for miRNAs in secretory dysfunction of the salivary 
glands (Alevizos et al. 2011). Later in 2011, we reported that miR-146a is significantly 
overexpressed in the PBMCs of SS patients compared to healthy controls and in the salivary 
glands and PBMCs of 8 week old C57BL/6.NOD-Aec1Aec2 female mice compared to wild-
type mice (Pauley et al. 2011). It is particularly interesting that miR-146a is upregulated in 
the target tissues (salivary glands) at 8 weeks of age since this is prior to disease onset in this 
mouse model. These data suggest that miR-146a could play a role in early disease 
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pathogenesis in SS or could be a result of altered glandular homeostasis prior to disease 
onset. 
Taken together, it is becoming increasingly clear that innate differences in the salivary 
glands of SS contribute to disease onset and/or loss of secretory function. Developmental 
defects, altered glandular homeostasis in the absence of immune cell infiltrates, and a 
tendency towards a proinflammatory environment are all evident in the salivary glands of 
SS mouse models, sometimes even prior to disease onset. It remains to be seen how these 
changes develop, but one hypothesis is that chronic stimulation by pathogens can lead to 
subclinical changes in the glands. In this case, it will be critical to identify the signatures left 
behind by these pathogens, such as viral or bacterial footprints, in order to use them as early 
disease markers to detect individuals susceptible to developing SS. 
 
Fig. 4. Mechanisms contributing to secretory dysfunction in SS salivary glands. 
3. Conclusion  
In conclusion, it is evident that numerous mechanisms contribute to salivary gland 
dysfunction in SS. The initial trigger of autoimmune reactivity and which of these 
mechanisms, if any, are more important in SS pathogenesis remains to be seen. Also, it is 
unclear whether pre-existing genetic factors predetermine certain individuals to develop SS, 
or if there is a specific environmental or immunological trigger. It would be interesting and 
very informative to transplant the salivary glands of a pre-disease SS-prone mouse to a 
www.intechopen.com
 
Mechanisms of Salivary Gland Secretory Dysfunction in Sjögren’s Syndrome 
 
185 
wild-type mouse to see if the recipient would still develop SS. This would identify whether 
a systemic environment or a glandular environment is critical for the onset of SS. Hopefully, 
ongoing research in the field of SS will lead to a better understanding of how the different 
mechanisms of secretory hypofunction discussed here can be prevented or circumvented to 
improve the quality of life of SS patients. There is a great need for potential new therapeutic 
strategies that can either turn off the autoimmune reaction in the exocrine tissue or 
preserve/replace the glandular tissue to restore secretory function. 
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